Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CDK2AP2

Gene summary for CDK2AP2

Gene summary.

Gene information	Species	Human
	Gene symbol	CDK2AP2
	Gene ID	10263
	Gene name	cyclin dependent kinase 2 associated protein 2
	Gene Alias	DOC-1R
	Cytomap	11q13.2
	Gene Type	protein-coding
	GO ID	GO:0000082
	UniProtAcc	O75956

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10263	CDK2AP2	HTA11_3410_2000001011	Human	Colorectum	AD	2.41e-11	3.35e-01	0.0155
10263	CDK2AP2	HTA11_2487_2000001011	Human	Colorectum	SER	1.43e-24	7.96e-01	-0.1808
10263	CDK2AP2	HTA11_2951_2000001011	Human	Colorectum	AD	2.31e-02	3.56e-01	0.0216
10263	CDK2AP2	HTA11_1938_2000001011	Human	Colorectum	AD	6.81e-27	9.13e-01	-0.0811
10263	CDK2AP2	HTA11_78_2000001011	Human	Colorectum	AD	1.63e-07	3.84e-01	-0.1088
10263	CDK2AP2	HTA11_347_2000001011	Human	Colorectum	AD	1.47e-37	7.85e-01	-0.1954
10263	CDK2AP2	HTA11_411_2000001011	Human	Colorectum	SER	9.35e-16	1.54e+00	-0.2602
10263	CDK2AP2	HTA11_2112_2000001011	Human	Colorectum	SER	1.71e-08	6.50e-01	-0.2196
10263	CDK2AP2	HTA11_3361_2000001011	Human	Colorectum	AD	7.89e-21	8.12e-01	-0.1207
10263	CDK2AP2	HTA11_83_2000001011	Human	Colorectum	SER	6.76e-24	8.70e-01	-0.1526
10263	CDK2AP2	HTA11_696_2000001011	Human	Colorectum	AD	1.24e-43	9.67e-01	-0.1464
10263	CDK2AP2	HTA11_866_2000001011	Human	Colorectum	AD	1.19e-16	5.38e-01	-0.1001
10263	CDK2AP2	HTA11_1391_2000001011	Human	Colorectum	AD	1.43e-43	1.21e+00	-0.059
10263	CDK2AP2	HTA11_2992_2000001011	Human	Colorectum	SER	3.63e-09	8.15e-01	-0.1706
10263	CDK2AP2	HTA11_5212_2000001011	Human	Colorectum	AD	3.54e-18	7.89e-01	-0.2061
10263	CDK2AP2	HTA11_5216_2000001011	Human	Colorectum	SER	8.64e-13	8.97e-01	-0.1462
10263	CDK2AP2	HTA11_546_2000001011	Human	Colorectum	AD	6.09e-15	6.72e-01	-0.0842
10263	CDK2AP2	HTA11_9341_2000001011	Human	Colorectum	SER	9.14e-03	6.28e-01	-0.00410000000000005
10263	CDK2AP2	HTA11_7862_2000001011	Human	Colorectum	AD	9.44e-09	4.65e-01	-0.0179
10263	CDK2AP2	HTA11_866_3004761011	Human	Colorectum	AD	1.39e-15	4.77e-01	0.096

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0007346	Colorectum	AD	regulation of mitotic cell cycle	119/3918	457/18723	4.60e-03	3.14e-02	119
GO:0070507	Colorectum	AD	regulation of microtubule cytoskeleton organization	44/3918	148/18723	7.05e-03	4.31e-02	44
GO:00073461	Colorectum	MSS	regulation of mitotic cell cycle	108/3467	457/18723	3.30e-03	2.50e-02	108
GO:000734610	Esophagus	HGIN	regulation of mitotic cell cycle	98/2587	457/18723	4.39e-06	1.42e-04	98
GO:00447729	Esophagus	HGIN	mitotic cell cycle phase transition	89/2587	424/18723	2.80e-05	7.21e-04	89
GO:19019906	Esophagus	HGIN	regulation of mitotic cell cycle phase transition	65/2587	299/18723	1.12e-04	2.36e-03	65
GO:20000456	Esophagus	HGIN	regulation of G1/S transition of mitotic cell cycle	36/2587	142/18723	1.74e-04	3.35e-03	36
GO:00000827	Esophagus	HGIN	G1/S transition of mitotic cell cycle	48/2587	214/18723	3.97e-04	6.07e-03	48
GO:00448437	Esophagus	HGIN	cell cycle G1/S phase transition	52/2587	241/18723	6.19e-04	8.58e-03	52
GO:19028065	Esophagus	HGIN	regulation of cell cycle G1/S phase transition	39/2587	168/18723	6.60e-04	9.03e-03	39
GO:20001343	Esophagus	HGIN	negative regulation of G1/S transition of mitotic cell cycle	23/2587	84/18723	7.90e-04	1.03e-02	23
GO:00459305	Esophagus	HGIN	negative regulation of mitotic cell cycle	49/2587	235/18723	1.88e-03	2.01e-02	49
GO:19019915	Esophagus	HGIN	negative regulation of mitotic cell cycle phase transition	39/2587	179/18723	2.31e-03	2.36e-02	39
GO:19028073	Esophagus	HGIN	negative regulation of cell cycle G1/S phase transition	23/2587	93/18723	3.39e-03	3.18e-02	23
GO:19019876	Esophagus	HGIN	regulation of cell cycle phase transition	72/2587	390/18723	5.78e-03	4.70e-02	72
GO:004477216	Esophagus	ESCC	mitotic cell cycle phase transition	281/8552	424/18723	4.63e-18	4.45e-16	281
GO:000734615	Esophagus	ESCC	regulation of mitotic cell cycle	293/8552	457/18723	8.00e-16	5.64e-14	293
GO:190198713	Esophagus	ESCC	regulation of cell cycle phase transition	242/8552	390/18723	3.86e-11	1.26e-09	242
GO:190199013	Esophagus	ESCC	regulation of mitotic cell cycle phase transition	191/8552	299/18723	1.35e-10	3.94e-09	191
GO:00457865	Esophagus	ESCC	negative regulation of cell cycle	236/8552	385/18723	3.62e-10	9.93e-09	236

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CDK2AP2

SNV

Missense_Mutation

c.359N>T

p.Thr120Ile

p.T120I

O75956

protein_coding

deleterious(0)

possibly_damaging(0.834)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

c.275N>G

p.Tyr92Cys

p.Y92C

O75956

protein_coding

deleterious(0)

probably_damaging(0.975)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

novel

c.302N>A

p.Arg101His

p.R101H

O75956

protein_coding

deleterious(0.02)

probably_damaging(0.995)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

CDK2AP2

SNV

Missense_Mutation

c.377N>T

p.Thr126Met

p.T126M

O75956

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-EI-6882-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

novel

c.200C>T

p.Ala67Val

p.A67V

O75956

protein_coding

tolerated(0.1)

benign(0.038)

TCGA-AJ-A2QO-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

novel

c.35G>T

p.Ser12Ile

p.S12I

O75956

protein_coding

tolerated_low_confidence(0.21)

benign(0.007)

TCGA-EO-A22U-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CDK2AP2

insertion

Nonsense_Mutation

novel

c.217_218insTTACTTTTAAAAACTGTTTTTAAATATACACGTAGACGAAAGTAC

p.Thr73delinsIleThrPheLysAsnCysPheTerIleTyrThrTerThrLysValPro

p.T73delinsITFKNCF*IYT*TKVP

O75956

protein_coding

TCGA-AX-A06B-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

c.221N>G

p.Tyr74Cys

p.Y74C

O75956

protein_coding

deleterious(0)

probably_damaging(0.992)

TCGA-CC-A7IH-01

Liver

liver hepatocellular carcinoma

Male

<65

III/IV

Unknown

CDK2AP2

SNV

Missense_Mutation

novel

c.125N>T

p.Ala42Val

p.A42V

O75956

protein_coding

deleterious(0.01)

benign(0.222)

TCGA-22-1002-01

Lung

lung squamous cell carcinoma

Male

>=65

I/II

Unknown

CDK2AP2

SNV

Missense_Mutation

c.179A>T

p.Gln60Leu

p.Q60L

O75956

protein_coding

deleterious(0.04)

benign(0.013)

TCGA-66-2727-01

Lung

lung squamous cell carcinoma

Female

<65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1